Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

October 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More
September 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

European Academy of Dermatology and Venereology (EADV) 2024
Read More
August 16, 2024

Journal of Medicinal Chemistry: Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases

Zheng, et al.
Read More
July 29, 2024

Journal of Investigative Dermatology: Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers

McDonald, et al.
Hidradenitis Suppurativa (HS)
Read More
May 22, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Model of Asthma

American Thoracic Society (ATS) 2024
Read More
May 21, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation In Vivo in a Mouse Model

Digestive Disease Week (DDW) 2024
Read More
March 8, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis

American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
March 8, 2024

Potent and Selective TYK2 degraders, Devoid of JAK Activity, Potently and Completely Suppress IL12/23 and Type I IFN Signaling Pathways

American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
November 14, 2023

IRAK4 Degradation vs Inhibition

IRAK4 Program Background
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
November 13, 2023

Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More